Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bristol-Myers Squibb Co BMY

Healthcare
Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule... see more

Recent & Breaking News (NYSE:BMY)

Bristol-Myers Squibb Continues Evolution to Specialty BioPharma Through Sale of Its Diabetes Business

Business Wire December 19, 2013

Bristol-Myers Squibb Foundation Awards $3.28 Million in Grants to Support Mental Health Needs of U.S. Military Service Members Returning from Afghanistan and Iraq

Business Wire December 17, 2013

FDA Advisory Committee Recommends the Investigational SGLT2 Inhibitor Dapagliflozin for the Treatment of Type 2 Diabetes in Adults

Business Wire December 12, 2013

FDA Advisory Committee Votes on Investigational Medicine Metreleptin

Business Wire December 11, 2013

Bristol-Myers Squibb Names Thomas J. Lynch, Jr., M.D. to Board of Directors

Business Wire December 10, 2013

Bristol-Myers Squibb Foundation Announces Two Grants to Fund Cancer Nursing Centers of Excellence in Russia and the Czech Republic

Business Wire December 10, 2013

Four-Year Data from Phase 3 DASISION Trial Comparing Sprycel® (dasatinib) to Imatinib in First-Line Treatment of Adults with Ph+ CP-CML Presented at Annual Meeting of the American Society of Hematology

Business Wire December 9, 2013

Xigduo(TM) (dapagliflozin and metformin hydrochloride) Receives Positive CHMP Opinion in the European Union for the Treatment of Type 2 Diabetes

Business Wire November 22, 2013

Bristol-Myers Squibb's innovative melanoma treatment Yervoy receives industry's highest honour

Canada NewsWire November 21, 2013

Bristol-Myers Squibb Foundation Marks World Diabetes Day with Four Grants Addressing Link Between Diabetes, Depression and Distress

Business Wire November 14, 2013

INNATE PHARMA : preclinical data opening new perspectives for development of Lirilumab in combination to be presented at ASH

Globe Newswire November 14, 2013

Bristol-Myers Squibb Announces Changes in Senior Management Team

Business Wire November 13, 2013

BMS Submits First All-Oral, Interferon-Free and Ribavirin-Free Treatment Regimen for Regulatory Review in Japan for Patients with Chronic Hepatitis C Infection

Business Wire November 2, 2013

IncellDx Signs Agreement With Bristol-Myers Squibb Related to the Development of an Assay for a Companion Diagnostic Test

Globe Newswire October 29, 2013

TrendingWallStreet.com Issues Volume Alerts on BMY, NECA, TDEY, and SNTA

Accesswire October 28, 2013

Promising Phase IIb Data On Clazakizumab In Patients With Moderate-To-Severe Rheumatoid Arthritis To Be Presented At The 2013 Annual Meeting Of The American College Of Rheumatology

Business Wire October 28, 2013

Howie Mandel Challenges People To Learn The Fibs And Facts About Atrial Fibrillation And Its Associated Increased Stroke Risk

Business Wire October 28, 2013

Additional Survival Data on Nivolumab, an Investigational PD-1 Immune Checkpoint Inhibitor, from Lung Cancer Cohort of a Phase 1 Study Presented at 15th World Conference on Lung Cancer

Business Wire October 25, 2013

Bristol-Myers Squibb Prices $1.5 Billion of Senior Notes

Business Wire October 24, 2013

Bristol-Myers Squibb Reports Third Quarter 2013 Financial Results

Business Wire October 23, 2013